- Home
- PRCT vs PTGX Comparison
PRCT vs PTGX Comparison
Compare PRCT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- PTGX
- Stock Information
- Founded
- PRCT 2009
- PTGX 2006
- Country
- PRCT United States
- PTGX United States
- Employees
- PRCT N/A
- PTGX N/A
- Industry
- PRCT Medical Specialities
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- PTGX Health Care
- Exchange
- PRCT Nasdaq
- PTGX Nasdaq
- Market Cap
- PRCT 3.2B
- PTGX 3.3B
- IPO Year
- PRCT 2021
- PTGX 2016
- Fundamental
- Price
- PRCT $55.72
- PTGX $55.15
- Analyst Decision
- PRCT Buy
- PTGX Strong Buy
- Analyst Count
- PRCT 8
- PTGX 9
- Target Price
- PRCT $86.14
- PTGX $67.11
- AVG Volume (30 Days)
- PRCT 1.0M
- PTGX 790.5K
- Earning Date
- PRCT 08-06-2025
- PTGX 08-05-2025
- Dividend Yield
- PRCT N/A
- PTGX N/A
- EPS Growth
- PRCT N/A
- PTGX N/A
- EPS
- PRCT N/A
- PTGX 0.86
- Revenue
- PRCT $249,121,000.00
- PTGX $207,801,000.00
- Revenue This Year
- PRCT $47.38
- PTGX N/A
- Revenue Next Year
- PRCT $31.71
- PTGX $53.09
- P/E Ratio
- PRCT N/A
- PTGX $63.95
- Revenue Growth
- PRCT 59.36
- PTGX N/A
- 52 Week Low
- PRCT $47.04
- PTGX $32.50
- 52 Week High
- PRCT $103.81
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- PRCT 42.58
- PTGX 56.72
- Support Level
- PRCT $55.76
- PTGX $51.55
- Resistance Level
- PRCT $60.57
- PTGX $57.73
- Average True Range (ATR)
- PRCT 3.08
- PTGX 1.74
- MACD
- PRCT -0.05
- PTGX -0.07
- Stochastic Oscillator
- PRCT 42.26
- PTGX 69.13
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.